BUZZ-Ionis shares fall as reiterated guidance misses expectations and drug sales outlook is lowered

November 9 - ** The share price of pharmaceutical company Ionis Pharmaceuticals (IONS.O) fell 17% in pre-market trading to $31.70

** The company reiterated its full-year revenue forecast is expected to be between $875 million and $900 million, below analysts' forecast of $916.4 million — data compiled by LSEG

** The report shows total revenue for the third quarter was $243 million, up 55% from the same period a year ago

** The report shows that the net sales of its hereditary disease drug Tryngolza in the U.S. for the third quarter were $9 million, below the market consensus expectation of $21 million

** The full-year sales forecast for “Tryngolza” was lowered by about $50 million to $100 to $110 million

** As of the previous trading day's close, the stock had fallen by a cumulative 50.2% for the year

(To assist non-native English speakers, Reuters has automatically translated its reporting into several other languages. Because automated translation may contain errors or may not fully convey the intended context, Reuters does not guarantee the accuracy of translated texts. These automated translations are provided for readers’ convenience only. Reuters shall not accept any liability for any damages or losses arising from the use of automated translation features.)